Fenofibrate is generally not recommended to be taken with pitavastatin unless the benefits of lipid modulation outweigh the risks, as prescribed by the physician. 1. Fenofibrate is indicated for adults with hyperlipidemia in whom dietary control therapies have not been effective, with a more pronounced effect on lowering triglycerides and mixed hyperlipidemia compared to cholesterol. Pitavastatin is suitable for the treatment of hypercholesterolemia and familial hypercholesterolemia. 2. Fenofibrate adverse reactions include abdominal discomfort, diarrhea, constipation, malaise, headache, impotence, loss of libido, dizziness, insomnia, and rash. Pitavastatin adverse reactions include abdominal pain, drug rash, tiredness, numbness, itching. 3. Fenofibrate is contraindicated in people who are allergic to fenofibrate, with a history of gallbladder disease, cholelithiasis, severe renal insufficiency, hepatic insufficiency, primary biliary cirrhosis, and persistent abnormalities of hepatic function for unknown reasons. Contraindications to pitavastatin are hypersensitivity to the product, pregnant and potentially pregnant women and lactating women, those with severe liver disease or biliary occlusion, and those taking cyclosporine. Fenofibrate and pitavastatin are not recommended to be taken together, mainly because the combination may increase the probability of adverse muscle events such as rhabdomyolysis. Specific dosing should be done under the guidance of a specialist.